Sleep quality in well-defined Lyme disease

A clinical cohort study in Maryland

Eric R. Weinstein, Alison W. Rebman, John N. Aucott, Douglas E Johnson-Greene, Kathleen T. Bechtold

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Study Objectives: Lyme disease (LD) is the most common vector-borne disease in the United States. Approximately 5-15 per cent of patients develop postantibiotic treatment symptoms termed post-treatment Lyme disease syndrome (PTLDS). The primary objective of this study is to examine and quantify sleep quality among patients with early LD during the acute and convalescent periods, including among the subset who met criteria for PTLDS. Methods: This paper draws from a clinical cohort study of participants with early LD (n = 122) and a subcohort of individuals who later met criteria for PTLDS (n = 6). Participants were followed for 1 year after antibiotic treatment. The Pittsburgh Sleep Quality Index and standardized measures of pain, fatigue, depressive symptoms, and functional impact were administered at all visits for participants and controls (n = 26). Participants meeting criteria for PTLDS at 1 year posttreatment were compared with a subset of PSQI-defined poor sleeping controls (n = 10). Results: At the pretreatment visit, participants with early LD reported poorer sleep than controls. By 6 months posttreatment, participant sleep scores as a group returned to control levels. Participants with PTLDS reported significantly worse global sleep and sleep disturbance scores and worse fatigue, functional impact, and more cognitive-affective depressive symptoms compared with poor sleeping controls. Conclusions: Participants with early LD experienced poor sleep quality, which is associated with typical LD symptoms of pain and fatigue. In the subset of patients who developed PTLDS, sleep quality remains affected for up to 1 year post-treatment and is commonly associated with pain. Sleep quality should be considered in the clinical picture for LD and PTLDS.

Original languageEnglish (US)
Article number035
JournalSleep
Volume41
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Lyme Disease
Sleep
Cohort Studies
Fatigue
Therapeutics
Clinical Studies
Pain
Depression
Disease Vectors
Affective Symptoms

Keywords

  • Lyme disease
  • Pittsburgh Sleep Quality Index
  • post-treatment Lyme disease syndrome
  • sleep and chronic pai
  • sleep quality

ASJC Scopus subject areas

  • Clinical Neurology
  • Physiology (medical)

Cite this

Sleep quality in well-defined Lyme disease : A clinical cohort study in Maryland. / Weinstein, Eric R.; Rebman, Alison W.; Aucott, John N.; Johnson-Greene, Douglas E; Bechtold, Kathleen T.

In: Sleep, Vol. 41, No. 5, 035, 01.05.2018.

Research output: Contribution to journalArticle

Weinstein, Eric R. ; Rebman, Alison W. ; Aucott, John N. ; Johnson-Greene, Douglas E ; Bechtold, Kathleen T. / Sleep quality in well-defined Lyme disease : A clinical cohort study in Maryland. In: Sleep. 2018 ; Vol. 41, No. 5.
@article{8fd9ce1ee75546fcae5d3d9e332f7102,
title = "Sleep quality in well-defined Lyme disease: A clinical cohort study in Maryland",
abstract = "Study Objectives: Lyme disease (LD) is the most common vector-borne disease in the United States. Approximately 5-15 per cent of patients develop postantibiotic treatment symptoms termed post-treatment Lyme disease syndrome (PTLDS). The primary objective of this study is to examine and quantify sleep quality among patients with early LD during the acute and convalescent periods, including among the subset who met criteria for PTLDS. Methods: This paper draws from a clinical cohort study of participants with early LD (n = 122) and a subcohort of individuals who later met criteria for PTLDS (n = 6). Participants were followed for 1 year after antibiotic treatment. The Pittsburgh Sleep Quality Index and standardized measures of pain, fatigue, depressive symptoms, and functional impact were administered at all visits for participants and controls (n = 26). Participants meeting criteria for PTLDS at 1 year posttreatment were compared with a subset of PSQI-defined poor sleeping controls (n = 10). Results: At the pretreatment visit, participants with early LD reported poorer sleep than controls. By 6 months posttreatment, participant sleep scores as a group returned to control levels. Participants with PTLDS reported significantly worse global sleep and sleep disturbance scores and worse fatigue, functional impact, and more cognitive-affective depressive symptoms compared with poor sleeping controls. Conclusions: Participants with early LD experienced poor sleep quality, which is associated with typical LD symptoms of pain and fatigue. In the subset of patients who developed PTLDS, sleep quality remains affected for up to 1 year post-treatment and is commonly associated with pain. Sleep quality should be considered in the clinical picture for LD and PTLDS.",
keywords = "Lyme disease, Pittsburgh Sleep Quality Index, post-treatment Lyme disease syndrome, sleep and chronic pai, sleep quality",
author = "Weinstein, {Eric R.} and Rebman, {Alison W.} and Aucott, {John N.} and Johnson-Greene, {Douglas E} and Bechtold, {Kathleen T.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1093/sleep/zsy035",
language = "English (US)",
volume = "41",
journal = "Sleep",
issn = "0161-8105",
publisher = "American Academy of Sleep Medicine",
number = "5",

}

TY - JOUR

T1 - Sleep quality in well-defined Lyme disease

T2 - A clinical cohort study in Maryland

AU - Weinstein, Eric R.

AU - Rebman, Alison W.

AU - Aucott, John N.

AU - Johnson-Greene, Douglas E

AU - Bechtold, Kathleen T.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Study Objectives: Lyme disease (LD) is the most common vector-borne disease in the United States. Approximately 5-15 per cent of patients develop postantibiotic treatment symptoms termed post-treatment Lyme disease syndrome (PTLDS). The primary objective of this study is to examine and quantify sleep quality among patients with early LD during the acute and convalescent periods, including among the subset who met criteria for PTLDS. Methods: This paper draws from a clinical cohort study of participants with early LD (n = 122) and a subcohort of individuals who later met criteria for PTLDS (n = 6). Participants were followed for 1 year after antibiotic treatment. The Pittsburgh Sleep Quality Index and standardized measures of pain, fatigue, depressive symptoms, and functional impact were administered at all visits for participants and controls (n = 26). Participants meeting criteria for PTLDS at 1 year posttreatment were compared with a subset of PSQI-defined poor sleeping controls (n = 10). Results: At the pretreatment visit, participants with early LD reported poorer sleep than controls. By 6 months posttreatment, participant sleep scores as a group returned to control levels. Participants with PTLDS reported significantly worse global sleep and sleep disturbance scores and worse fatigue, functional impact, and more cognitive-affective depressive symptoms compared with poor sleeping controls. Conclusions: Participants with early LD experienced poor sleep quality, which is associated with typical LD symptoms of pain and fatigue. In the subset of patients who developed PTLDS, sleep quality remains affected for up to 1 year post-treatment and is commonly associated with pain. Sleep quality should be considered in the clinical picture for LD and PTLDS.

AB - Study Objectives: Lyme disease (LD) is the most common vector-borne disease in the United States. Approximately 5-15 per cent of patients develop postantibiotic treatment symptoms termed post-treatment Lyme disease syndrome (PTLDS). The primary objective of this study is to examine and quantify sleep quality among patients with early LD during the acute and convalescent periods, including among the subset who met criteria for PTLDS. Methods: This paper draws from a clinical cohort study of participants with early LD (n = 122) and a subcohort of individuals who later met criteria for PTLDS (n = 6). Participants were followed for 1 year after antibiotic treatment. The Pittsburgh Sleep Quality Index and standardized measures of pain, fatigue, depressive symptoms, and functional impact were administered at all visits for participants and controls (n = 26). Participants meeting criteria for PTLDS at 1 year posttreatment were compared with a subset of PSQI-defined poor sleeping controls (n = 10). Results: At the pretreatment visit, participants with early LD reported poorer sleep than controls. By 6 months posttreatment, participant sleep scores as a group returned to control levels. Participants with PTLDS reported significantly worse global sleep and sleep disturbance scores and worse fatigue, functional impact, and more cognitive-affective depressive symptoms compared with poor sleeping controls. Conclusions: Participants with early LD experienced poor sleep quality, which is associated with typical LD symptoms of pain and fatigue. In the subset of patients who developed PTLDS, sleep quality remains affected for up to 1 year post-treatment and is commonly associated with pain. Sleep quality should be considered in the clinical picture for LD and PTLDS.

KW - Lyme disease

KW - Pittsburgh Sleep Quality Index

KW - post-treatment Lyme disease syndrome

KW - sleep and chronic pai

KW - sleep quality

UR - http://www.scopus.com/inward/record.url?scp=85047197784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047197784&partnerID=8YFLogxK

U2 - 10.1093/sleep/zsy035

DO - 10.1093/sleep/zsy035

M3 - Article

VL - 41

JO - Sleep

JF - Sleep

SN - 0161-8105

IS - 5

M1 - 035

ER -